Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment

Simply Wall St.03-11

Travere Therapeutics (TVTX) is drawing attention after reporting strong U.S. net product sales growth driven by FILSPARI and outlining expectations for a US$25 million sales based milestone payment ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618963396?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-11 00:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618963396","market":"hk","top_or_hot":-1,"title":"Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment","media":"Simply Wall St.","content":"<div>\n<p>Travere Therapeutics (TVTX) is drawing attention after reporting strong U.S. net product sales growth driven by FILSPARI and outlining expectations for a US$25 million sales based milestone payment ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-after-filspari\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Travere Therapeutics (TVTX) Valuation After FILSPARI Sales Momentum And Expected Mirum Milestone Payment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-11 00:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-after-filspari><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Travere Therapeutics (TVTX) is drawing attention after reporting strong U.S. net product sales growth driven by FILSPARI and outlining expectations for a US$25 million sales based milestone payment ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-after-filspari\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-after-filspari","article_id":"2618963396","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/assessing-travere-therapeutics-tvtx-valuation-after-filspari","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618963396","pubTimestamp":1773159313,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Travere Therapeutics (TVTX) is drawing attention after reporting strong U.S. net product sales growth driven by FILSPARI and outlining expectations for a US$25 million sales based milestone payment from Mirum Pharmaceuticals in early 2026.\nSee our latest analysis for Travere Therapeutics.\nThe recent update on FILSPARI sales and the expected Mirum milestone comes after a tough stretch for the share price, with a year to date share price return of negative 26.67% and a 90 day share price return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"在FILSPARI销售势头和预期Mirum里程碑付款后评估Travere Therapeutics(TVTX)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1.5},"content_text":"Travere Therapeutics (TVTX) is drawing attention after reporting strong U.S. net product sales growth driven by FILSPARI and outlining expectations for a US$25 million sales based milestone payment from Mirum Pharmaceuticals in early 2026. See our latest analysis for Travere Therapeutics. The recent update on FILSPARI sales and the expected Mirum milestone comes after a tough stretch for the share price, with a year to date share price return of negative 26.67% and a 90 day share price return of negative 16.02%. This is in contrast to the 1 year total shareholder return of 62.17% and 3 year total shareholder return of 33.36%, suggesting long term holders have seen very different outcomes from short term traders around the current US$28.98 level. If this kind of biotech news has your attention, it could be a good time to see what else is out there through our screener of 32 healthcare AI stocks. You might find a few fresh ideas to research next. With Travere shares down year to date despite annual revenue growth of 20.22% and an annual improvement in net income of 49.81%, while also trading at a 47% discount to analyst targets, investors may question whether this represents a potential entry point or if the market is already accounting for future growth. AdvertisementMost Popular Narrative: 31.6% Undervalued Travere's most followed narrative sets a fair value of $42.36 per share against the latest close at $28.98, framing a clear valuation gap for investors to think about.  Travere's strengthening financial position, driven by rapid product sales growth, increased international out-licensing revenues, significant reductions in net losses, and prudent R&D and SG&A management, sets a foundation for positive net earnings while securing resources for continued pipeline development and future commercial launches. (Earnings, cash flow, R&D investment)  Read the complete narrative. Want to see how this story translates into numbers? Revenue, margins and future earnings power are all wired into this fair value. The full narrative lays out the math behind that $42.36 figure. Result: Fair Value of $42.36 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on FILSPARI maintaining its edge in a crowded kidney space and on the FSGS review process not slipping or tightening unexpectedly. Find out about the key risks to this Travere Therapeutics narrative. Next Steps With the mix of risks and rewards you have just read about, it makes sense to check the numbers yourself and decide where you stand. Our breakdown of 5 key rewards and 1 important warning sign can help you weigh both sides quickly. Looking for more investment ideas? If this update has you thinking bigger than a single stock, now is the moment to widen your watchlist and hunt for ideas that truly fit your approach.  Target potential mispricings by scanning 46 high quality undervalued stocks that might offer a more attractive entry point than what is already on your radar. Lock in potential income ideas by reviewing a curated set of 14 dividend fortresses that focus on higher yields with staying power. Stay on the front foot by checking our 63 resilient stocks with low risk scores that prioritize resilience when conditions get choppy.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Travere Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618963396","isCrawlerRequest":true}